Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.

ABSTRACT: Metastatic hormone-sensitive prostate cancer (mHSPC) often progresses to castration-resistant prostate cancer despite current therapies, necessitating the use of reliable biomarkers. This study aimed to develop a novel model for predicting progression-free survival (PFS) using ctDNA sequencing. We analyzed 127 patients with mHSPC and compared ctDNA mutations with those in matched primary tumor tissues. A four-gene signature (TRPC: TP53, RB1, PTEN, and CDK12) was identified, forming the basis of the blood-based TRPC (b.TRPC) model. The b.TRPC model demonstrated high specificity and sensitivity in predicting PFS, outperforming ctDNA markers. Internal and external validation confirmed that b.TRPC is an independent prognostic factor with superior predictive performance for 0.5-, 1-, and 2-year

SUBMITTER: Wang R 

PROVIDER: S-EPMC12665648 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature